Davis Polk Advises Roche In $230M Deal To Buy Anadys

Law360, New York (October 17, 2011, 2:37 PM EDT) -- Swiss drug giant Roche Holding AG said Monday it had agreed to buy Anadys Pharmaceuticals Inc. for roughly $230 million to boost its offerings for treating hepatitis C.

Roche will pay $3.70 per share in an all-cash deal. The transaction will give Roche access to Anadys' main hepatitis drug setrobuvir, which has shown positive results in a Phase II clinical trial involving Roche drugs, as well as ANA773, which is in phase I clinical trials and could also treat other chronic infections and cancer.

“This acquisition...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.